TECVAYLI® Monotherapy Shows Superior Survival vs Standard Care in Early Relapsed, Heavily Pretreated Myeloma

TECVAYLI® Monotherapy Shows Superior Survival vs. Standard Care in Early Relapsed, Heavily Pretreated Multiple Myeloma Johnson & Johnson, a worldwide leader in multiple myeloma therapies, today announced positive topline results…

Read MoreTECVAYLI® Monotherapy Shows Superior Survival vs Standard Care in Early Relapsed, Heavily Pretreated Myeloma